.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX02_GemtuzumabOzogamicin.GemtuzumabOzogamicin .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX02_GemtuzumabOzogamicin.GemtuzumabOzogamicin| name: | GemtuzumabOzogamicin |
| ATC code: | L01FX02 | route: | intravenous |
| n-compartments | 2 |
Gemtuzumab ozogamicin is a CD33-directed antibody-drug conjugate (ADC) comprised of a humanized monoclonal antibody linked to the cytotoxic agent calicheamicin. It is indicated for the treatment of adults with newly diagnosed or relapsed/refractory CD33-positive acute myeloid leukemia (AML). The drug is currently approved in several countries including the US and EU.
Pharmacokinetics reported in adult patients with relapsed or refractory AML. The model described is for the total antibody after intravenous administration (IV infusion).
Masters, JC, et al., & Knight, B (2019). Population Pharmacokinetics of Gemtuzumab Ozogamicin in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clinical pharmacokinetics 58(2) 271–282. DOI:10.1007/s40262-018-0694-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/30022367
Buckwalter, M, et al., & Mayer, PR (2004). Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. Journal of clinical pharmacology 44(8) 873–880. DOI:10.1177/0091270004267595 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15286091